Cargando…
A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment
PURPOSE: The aim of this audit was to assess the overall experience and patient convenience of vaginal progesterone tablets (Lutigest(®), marketed as Endometrin(®) in the USA) used for luteal phase support (LPS) during in vitro fertilization (IVF) treatment. PATIENTS AND METHODS: This questionnaire-...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726362/ https://www.ncbi.nlm.nih.gov/pubmed/29263708 http://dx.doi.org/10.2147/PROM.S140678 |
_version_ | 1783285707664523264 |
---|---|
author | Heine, Polly Sellar, Laura Whitten, Sue Bajaj, Priti |
author_facet | Heine, Polly Sellar, Laura Whitten, Sue Bajaj, Priti |
author_sort | Heine, Polly |
collection | PubMed |
description | PURPOSE: The aim of this audit was to assess the overall experience and patient convenience of vaginal progesterone tablets (Lutigest(®), marketed as Endometrin(®) in the USA) used for luteal phase support (LPS) during in vitro fertilization (IVF) treatment. PATIENTS AND METHODS: This questionnaire-based audit included responses from 100 patients undergoing IVF treatment at six IVF clinics in the UK from September 2015 to November 2016. Fourteen days after starting progesterone supplementation for LPS during their IVF treatment, patients rated overall experience and perceived convenience of the prescribed progesterone by completing a questionnaire. RESULTS: Of the 100 patients included, 96 received vaginal progesterone tablets for LPS. Overall, 53.1% (51/96) indicated that the progesterone tablets were “very easy” to use; 42.7% (41/96) and 44.8% (43/96) found it “very convenient” or “neither convenient or inconvenient” to administer the tablet, respectively. Overall experience with using progesterone tablets was rated as “very comfortable” by 34.4% (33/96) and “neither comfortable or uncomfortable” by 56.3% (54/96) of patients. The applicator was used by 93.8% (90/96) of patients to administer the tablet, and 86.5% (83/96) indicated that the applicator was easy to clean for repeated use. A total of 33 patients had a previous IVF cycle during which they were prescribed vaginal progesterone pessaries for LPS. Compared with progesterone pessaries, the majority found treatment with progesterone tablets to be more comfortable (60.6%; 20/33) and more convenient (57.6%; 19/33) and indicated that the progesterone tablet was their preferred progesterone formulation for LPS (60.6%; 20/33). CONCLUSION: These findings offer insights into real-world patient experiences with the progesterone vaginal tablet formulation. The results suggest overall patient convenience, ease, and comfort with using progesterone vaginal tablets for LPS. The majority of patients found progesterone vaginal tablets more convenient and comfortable to use compared with progesterone pessaries. |
format | Online Article Text |
id | pubmed-5726362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57263622017-12-20 A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment Heine, Polly Sellar, Laura Whitten, Sue Bajaj, Priti Patient Relat Outcome Meas Original Research PURPOSE: The aim of this audit was to assess the overall experience and patient convenience of vaginal progesterone tablets (Lutigest(®), marketed as Endometrin(®) in the USA) used for luteal phase support (LPS) during in vitro fertilization (IVF) treatment. PATIENTS AND METHODS: This questionnaire-based audit included responses from 100 patients undergoing IVF treatment at six IVF clinics in the UK from September 2015 to November 2016. Fourteen days after starting progesterone supplementation for LPS during their IVF treatment, patients rated overall experience and perceived convenience of the prescribed progesterone by completing a questionnaire. RESULTS: Of the 100 patients included, 96 received vaginal progesterone tablets for LPS. Overall, 53.1% (51/96) indicated that the progesterone tablets were “very easy” to use; 42.7% (41/96) and 44.8% (43/96) found it “very convenient” or “neither convenient or inconvenient” to administer the tablet, respectively. Overall experience with using progesterone tablets was rated as “very comfortable” by 34.4% (33/96) and “neither comfortable or uncomfortable” by 56.3% (54/96) of patients. The applicator was used by 93.8% (90/96) of patients to administer the tablet, and 86.5% (83/96) indicated that the applicator was easy to clean for repeated use. A total of 33 patients had a previous IVF cycle during which they were prescribed vaginal progesterone pessaries for LPS. Compared with progesterone pessaries, the majority found treatment with progesterone tablets to be more comfortable (60.6%; 20/33) and more convenient (57.6%; 19/33) and indicated that the progesterone tablet was their preferred progesterone formulation for LPS (60.6%; 20/33). CONCLUSION: These findings offer insights into real-world patient experiences with the progesterone vaginal tablet formulation. The results suggest overall patient convenience, ease, and comfort with using progesterone vaginal tablets for LPS. The majority of patients found progesterone vaginal tablets more convenient and comfortable to use compared with progesterone pessaries. Dove Medical Press 2017-12-08 /pmc/articles/PMC5726362/ /pubmed/29263708 http://dx.doi.org/10.2147/PROM.S140678 Text en © 2017 Heine et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Heine, Polly Sellar, Laura Whitten, Sue Bajaj, Priti A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment |
title | A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment |
title_full | A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment |
title_fullStr | A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment |
title_full_unstemmed | A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment |
title_short | A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest(®)) for luteal phase support during IVF treatment |
title_sort | questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (lutigest(®)) for luteal phase support during ivf treatment |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726362/ https://www.ncbi.nlm.nih.gov/pubmed/29263708 http://dx.doi.org/10.2147/PROM.S140678 |
work_keys_str_mv | AT heinepolly aquestionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment AT sellarlaura aquestionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment AT whittensue aquestionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment AT bajajpriti aquestionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment AT heinepolly questionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment AT sellarlaura questionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment AT whittensue questionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment AT bajajpriti questionnairebasedaudittoassessoverallexperienceandconvenienceamongpatientsusingvaginalprogesteronetabletslutigestforlutealphasesupportduringivftreatment |